Procaps Group SA

NASDAQ:PROC USA Drug Manufacturers - Specialty & Generic
Market Cap
$124.11 Million
Market Cap Rank
#25753 Global
#8761 in USA
Share Price
$1.10
Change (1 day)
+0.00%
52-Week Range
$0.53 - $1.47
All Time High
$10.76
About

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use… Read more

Procaps Group SA (PROC) - Total Liabilities

Latest total liabilities as of September 2023: $460.10 Million USD

Based on the latest financial reports, Procaps Group SA (PROC) has total liabilities worth $460.10 Million USD as of September 2023.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Procaps Group SA - Total Liabilities Trend (2019–2022)

This chart illustrates how Procaps Group SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Procaps Group SA Competitors by Total Liabilities

The table below lists competitors of Procaps Group SA ranked by their total liabilities.

Liability Composition Analysis (2019–2022)

This chart breaks down Procaps Group SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.47 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 11.68 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.92 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Procaps Group SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Procaps Group SA (2019–2022)

The table below shows the annual total liabilities of Procaps Group SA from 2019 to 2022.

Year Total Liabilities Change
2022-12-31 $462.06 Million -7.67%
2021-12-31 $500.48 Million -18.52%
2020-12-31 $614.22 Million +5.59%
2019-12-31 $581.67 Million --